Cargando…

Identification of novel bacterial DNA gyrase inhibitors: An in silico study

Owing to essential role in bacterial survival, DNA gyrase has been exploited as a validated drug target. However, rapidly emerging resistance to gyrase-targeted drugs such as widely utilized fluoroquinolones reveals the necessity to develop novel compounds with new mechanism of actions against this...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahimi, Hamzeh, Najafi, Ali, Eslami, Habib, Negahdari, Babak, Moghaddam, Mehrdad Moosazadeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962306/
https://www.ncbi.nlm.nih.gov/pubmed/27499795
_version_ 1782444810003546112
author Rahimi, Hamzeh
Najafi, Ali
Eslami, Habib
Negahdari, Babak
Moghaddam, Mehrdad Moosazadeh
author_facet Rahimi, Hamzeh
Najafi, Ali
Eslami, Habib
Negahdari, Babak
Moghaddam, Mehrdad Moosazadeh
author_sort Rahimi, Hamzeh
collection PubMed
description Owing to essential role in bacterial survival, DNA gyrase has been exploited as a validated drug target. However, rapidly emerging resistance to gyrase-targeted drugs such as widely utilized fluoroquinolones reveals the necessity to develop novel compounds with new mechanism of actions against this enzyme. Here, an attempt has been made to identify new drug-like molecules for Shigella flexneri DNA gyrase inhibition through in silico approaches. The structural similarity search was carried out using the natural product simocyclinone D8, a unique gyrase inhibitor, to virtually screen ZINC database. A total of 11830 retrieved hits were further screened for selection of high-affinity compounds by implementing molecular docking followed by investigation of druggability according to Lipinski’s rule, biological activity and physiochemical properties. Among the hits initially identified, three molecules were then confirmed to have reasonable gyrase-binding affinity and to follow Lipinski’s rule. Based on these in silico findings, three compounds with different chemical structures from previously identified gyrase inhibitors were proposed as potential candidates for the treatment of fluoroquinolone-resistant strains and deserve further investigations.
format Online
Article
Text
id pubmed-4962306
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-49623062016-08-05 Identification of novel bacterial DNA gyrase inhibitors: An in silico study Rahimi, Hamzeh Najafi, Ali Eslami, Habib Negahdari, Babak Moghaddam, Mehrdad Moosazadeh Res Pharm Sci Original Article Owing to essential role in bacterial survival, DNA gyrase has been exploited as a validated drug target. However, rapidly emerging resistance to gyrase-targeted drugs such as widely utilized fluoroquinolones reveals the necessity to develop novel compounds with new mechanism of actions against this enzyme. Here, an attempt has been made to identify new drug-like molecules for Shigella flexneri DNA gyrase inhibition through in silico approaches. The structural similarity search was carried out using the natural product simocyclinone D8, a unique gyrase inhibitor, to virtually screen ZINC database. A total of 11830 retrieved hits were further screened for selection of high-affinity compounds by implementing molecular docking followed by investigation of druggability according to Lipinski’s rule, biological activity and physiochemical properties. Among the hits initially identified, three molecules were then confirmed to have reasonable gyrase-binding affinity and to follow Lipinski’s rule. Based on these in silico findings, three compounds with different chemical structures from previously identified gyrase inhibitors were proposed as potential candidates for the treatment of fluoroquinolone-resistant strains and deserve further investigations. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4962306/ /pubmed/27499795 Text en Copyright: © Research in Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Rahimi, Hamzeh
Najafi, Ali
Eslami, Habib
Negahdari, Babak
Moghaddam, Mehrdad Moosazadeh
Identification of novel bacterial DNA gyrase inhibitors: An in silico study
title Identification of novel bacterial DNA gyrase inhibitors: An in silico study
title_full Identification of novel bacterial DNA gyrase inhibitors: An in silico study
title_fullStr Identification of novel bacterial DNA gyrase inhibitors: An in silico study
title_full_unstemmed Identification of novel bacterial DNA gyrase inhibitors: An in silico study
title_short Identification of novel bacterial DNA gyrase inhibitors: An in silico study
title_sort identification of novel bacterial dna gyrase inhibitors: an in silico study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962306/
https://www.ncbi.nlm.nih.gov/pubmed/27499795
work_keys_str_mv AT rahimihamzeh identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy
AT najafiali identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy
AT eslamihabib identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy
AT negahdaribabak identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy
AT moghaddammehrdadmoosazadeh identificationofnovelbacterialdnagyraseinhibitorsaninsilicostudy